Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.
Press Releases
Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 5, 2020
CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly statistically significant improvement in coronary flow reserve and angina symptoms CLBS12 registration eligible […]
Read MoreCaladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time
February 27, 2020
BASKING RIDGE, N.J. (February 27, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming February Conferences
February 3, 2020
BASKING RIDGE, N.J. (February 3, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming January Conferences
January 7, 2020
BASKING RIDGE, N.J. (January 7, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming December Conferences
December 2, 2019
BASKING RIDGE, N.J. (December 2, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
November 16, 2019
Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment […]
Read MoreCaladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update
November 6, 2019
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 6, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage […]
Read MoreCaladrius Biosciences to Participate at Upcoming November Conferences
October 31, 2019
BASKING RIDGE, N.J. (October 31, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell […]
Read MoreCaladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time
October 30, 2019
BASKING RIDGE, N.J. (October 30, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at the Upcoming October Conferences
October 1, 2019
BASKING RIDGE, N.J. (October 1, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at the Upcoming September Conferences
September 5, 2019
BASKING RIDGE, N.J. (September 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update
August 8, 2019
Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August […]
Read MoreCaladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina
August 7, 2019
BASKING RIDGE, NJ, AND MEMPHIS, TENN. (August 7, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements […]
Read MoreCaladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time
August 1, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select […]
Read MoreCaladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia
July 15, 2019
BASKING RIDGE, N.J. (July 15, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction
June 4, 2019
Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction Topline results expected by the end of 2019 BASKING RIDGE, N.J. (June 4, […]
Read MoreCaladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update
May 9, 2019
All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to […]
Read MoreCaladrius Biosciences to Participate at the Upcoming May Conferences
May 7, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that […]
Read MoreCaladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time
May 2, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that […]
Read MoreCaladrius Biosciences to Participate in Upcoming Conferences
April 3, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products […]
Read More